BioCardia (NASDAQ:BCDA) Shares Up 12.1% – Still a Buy?

BioCardia, Inc. (NASDAQ:BCDA)’s share price was up 12.1% on Friday . The company traded as high as $1.80 and last traded at $1.03. Approximately 150,596,959 shares were traded during trading, an increase of 39,885% from the average daily volume of 376,629 shares. The stock had previously closed at $0.9190.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of BioCardia in a research note on Monday, April 20th. One investment analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, BioCardia has a consensus rating of “Hold” and a consensus price target of $25.00.

BioCardia Price Performance

The stock has a market cap of $11.72 million, a price-to-earnings ratio of -1.13 and a beta of 0.51. The stock’s 50 day simple moving average is $1.09 and its two-hundred day simple moving average is $1.22.

BioCardia (NASDAQ:BCDA) last announced its quarterly earnings data on Friday, May 15th. The company reported ($0.21) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.17) by ($0.04). As a group, analysts predict that BioCardia, Inc. will post -0.71 earnings per share for the current year.

Institutional Trading of BioCardia

Large investors have recently added to or reduced their stakes in the company. Cetera Investment Advisers acquired a new position in shares of BioCardia in the 2nd quarter worth approximately $40,000. DRW Securities LLC bought a new position in shares of BioCardia in the fourth quarter worth about $72,000. Finally, Geode Capital Management LLC increased its holdings in shares of BioCardia by 70.4% in the fourth quarter. Geode Capital Management LLC now owns 66,003 shares of the company’s stock valued at $83,000 after purchasing an additional 27,263 shares in the last quarter. 20.57% of the stock is owned by institutional investors.

BioCardia Company Profile

BioCardia, Inc is a clinical-stage biotechnology company dedicated to developing novel cell-based therapies for patients with cardiovascular disease. The company’s core focus lies in advancing regenerative medicine approaches that address both chronic heart failure and acute myocardial infarction. BioCardia leverages proprietary delivery technologies to optimize the targeted administration of therapeutic cells directly into the heart muscle.

The company’s flagship products include the Helix Transendocardial Delivery System and the CardiAMP Cell Therapy System.